文献速递免疫规划传染病防控与疫情报告

5至17岁儿童和青少年COVID-19疫苗有效性:基于六个欧洲国家电子健康登记系统的多中心队列研究,2021至2022年

COVID-19 vaccine effectiveness in the paediatric population aged 5-17 years: a multicentre cohort study using electronic health registries in six European countries, 2021 to 2022.
PubMed 文献 · Euro Surveill · 2025-01-01

该研究利用丹麦、挪威、意大利、卢森堡、纳瓦拉(西班牙)和葡萄牙的常规电子健康登记系统建立固定队列,随访12个月,纳入4,144,667名5-11岁儿童和3,861,841名12-17岁青少年,评估COVID-19疫苗对实验室确诊SARS-CoV-2感染或COVID-19为主诊断的住院的有效性。在无既往感染的12-17岁人群中,总体疫苗有效性为69%(95%CI:40至84),随时间从接种后≤3个月的77%下降至180-365天的48%,Delta、Omicron BA.1/BA.2和BA.4/BA.5时期分别为94%(95%CI:90至96)、56%(95%CI:3至80)和41%(95%CI:-14至69)。有既往感染的12-17岁人群中,一剂疫苗有效性为80%(95%CI:18至95)。5-11岁人群估计值相似但精确度较低。结论认为推荐用于5-17岁人群的疫苗可提供针对COVID-19住院的保护,无论是否有既往SARS-CoV-2感染,接种后前3个月保护水平高。

要点

  • 无既往感染的12-17岁人群总体疫苗有效性为69%(95%CI:40至84)。
  • 疫苗有效性随接种时间从≤3个月的77%下降至180-365天的48%。
  • 有既往感染的12-17岁人群一剂疫苗有效性为80%(95%CI:18至95)。

核心结论

  • 推荐用于5-17岁人群的疫苗可提供针对COVID-19住院的保护,无论是否有既往SARS-CoV-2感染,接种后前3个月保护水平高。

研究设计与样本

  • 在丹麦、挪威、意大利、卢森堡、纳瓦拉(西班牙)和葡萄牙利用常规电子健康登记系统建立固定队列,随访12个月,各站点于2021年6月至2022年1月启动儿童COVID-19疫苗接种活动。
  • 纳入4,144,667名5-11岁儿童和3,861,841名12-17岁青少年。
  • 结局为以实验室确诊SARS-CoV-2感染或COVID-19为主诊断的住院。
  • 使用Cox比例风险模型估计疫苗有效性为1减去接种与未接种之间COVID-19住院的混杂因素调整风险比,并使用随机效应Meta分析合并疫苗有效性估计值。

主要发现

  • 无既往感染的12-17岁人群总体疫苗有效性为69%(95%CI:40至84)。
  • 无既往感染的12-17岁人群疫苗有效性随接种时间从≤3个月的77%下降至180-365天的48%。
  • 无既往感染的12-17岁人群疫苗有效性在Delta、Omicron BA.1/BA.2和BA.4/BA.5时期分别为94%(95%CI:90至96)、56%(95%CI:3至80)和41%(95%CI:-14至69)。
  • 有既往感染的12-17岁人群一剂疫苗有效性为80%(95%CI:18至95)。
  • 5-11岁人群疫苗有效性估计值与12-17岁人群相似但精确度较低。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BackgroundDuring the first year of the COVID-19 pandemic, vaccination programmes targeted children and adolescents to prevent severe outcomes of SARS-CoV-2 infection.AimTo estimate COVID-19 vaccine effectiveness (VE) against hospitalisation due to COVID-19 in the paediatric population, among those with and without previously documented SARS-CoV-2 infection.MethodsWe established a fixed cohort followed for 12 months in Denmark, Norway, Italy, Luxembourg, Navarre (Spain) and Portugal using routine electronic health registries. The study commenced with paediatric COVID-19 vaccination campaign at each site between June 2021 and January 2022. The outcome was hospitalisation with a laboratory-confirmed SARS-CoV-2 infection or COVID-19 as the main diagnosis. Using Cox proportional hazard models, VE was estimated as 1 minus the confounder-adjusted hazard ratio of COVID-19 hospitalisation between vaccinated and unvaccinated. A random-effects meta-analysis was used to pool VE estimates.ResultsWe included 4,144,667 5-11-year-olds and 3,861,841 12-17-year-olds. In 12-17-year-olds without previous infection, overall VE was 69% (95% CI: 40 to 84). VE declined with time since vaccination from 77% ≤ 3 months to 48% 180-365 days after immunisation. VE was 94% (95% CI: 90 to 96), 56% (95% CI: 3 to 80) and 41% (95% CI: -14 to 69) in the Delta, Omicron BA.1/BA.2 and BA.4/BA.5 periods, respectively. In 12-17-year-olds with previous infection, one dose VE was 80% (95% CI: 18 to 95). VE estimates were similar for 5-11-year-olds but with lower precision.ConclusionVaccines recommended for 5-17-year-olds provided protection against COVID-19 hospitalisation, regardless of a previously documented infection of SARS-CoV-2, with high levels of protection in the first 3 months of the vaccination.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Soares P, Machado A, Nicolay N, et al. COVID-19 vaccine effectiveness in the paediatric population aged 5-17 years: a multicentre cohort study using electronic health registries in six European countries, 2021 to 2022. Euro Surveill. 2025. PMID: 40017392. doi:10.2807/1560-7917.ES.2025.30.8.2400450

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。